|
1
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella- Branger D, Cavenee WK, Ohgaki H, Wiestler
OD, Kleihues P and Ellison DW: The 2016 World health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ostrom QT, Gittleman H, Liao P,
Vecchione-Koval T, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and other central nervous
system tumors diagnosed in the United States in 2010–2014. Neuro
Oncol. 19 (Suppl_5):v1–v88. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alifieris C and Trafalis DT: Glioblastoma
multiforme: Pathogenesis and treatment. Pharmacol Ther. 152:63–82.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cloughesy TF, Cavenee WK and Mischel PS:
Glioblastoma: From molecular pathology to targeted treatment. Annu
Rev Pathol. 9:1–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lim M, Xia Y, Bettegowda C and Weller M:
Current state of immunotherapy for glioblastoma. Nat Rev Clin
Oncol. 15:422–442. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel BP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dong H, Lei J, Ding L, Wen Y, Ju H and
Zhang X: MicroRNA: Function, detection, and bioanalysis. Chem Rev.
113:6207–6233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bracken CP, Scott HS and Goodall GJ: A
network-biology perspective of microRNA function and dysfunction in
cancer. Nat Rev Genet. 17:719–732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer
A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J,
et al: An extensive microRNA-mediated network of RNA-RNA
interactions regulates established oncogenic pathways in
glioblastoma. Cell. 147:370–381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Godlewski J, Nowicki MO, Bronisz A, Nuovo
G, Palatini J, De Lay M, Van Brocklyn J, Ostrowski MC, Chiocca EA
and Lawler SE: MicroRNA-451 regulates LKB1/AMPK signaling and
allows adaptation to metabolic stress in glioma cells. Mol Cell.
37:620–632. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu J, Sun T, Wang H, Chen Z, Wang S, Yuan
L, Liu T, Li HR, Wang P, Feng Y, et al: MiR-215 is induced
post-transcriptionally via HIF-Drosha complex and mediates
glioma-initiating cell adaptation to hypoxia by targeting
KDM1B. Cancer Cell. 29:49–60. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Berindan-Neagoe I, Monroig Pdel C,
Pasculli B and Calin GA: MicroRNAome genome: A treasure for cancer
diagnosis and therapy. CA Cancer J Clin. 64:311–336. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Subramanian A, Narayan R, Corsello SM,
Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK,
et al: A next generation connectivity map: L1000 platform and the
first 1,000,000 profiles. Cell. 171:1437–1452.e17. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qu XA and Rajpal DK: Applications of
connectivity map in drug discovery and development. Drug Discov
Today. 17:1289–1298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chien W, Sun QY, Lee KL, Ding LW, Wuensche
P, Torres-Fernandez LA, Tan SZ, Tokatly I, Zaiden N, Poellinger L,
et al: Activation of protein phosphatase 2A tumor suppressor as
potential treatment of pancreatic cancer. Mol Oncol. 9:889–905.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lamb J: The connectivity map: A new tool
for biomedical research. Nat Rev Cancer. 7:54–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Clough E and Barrett T: The gene
expression omnibus database. Methods Mol Biol. 1418:93–110. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression
analyses for RNA-sequencing and microarray studies. Nucleic Acids
Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kolde R, Laur S, Adler P and Vilo J:
Robust rank aggregation for gene list integration and
meta-analysis. Bioinformatics. 28:573–580. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dweep H, Gretz N and Sticht C: miRWalk
database for miRNA- target interactions. Methods Mol Biol.
1182:289–305. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Musa A, Ghoraie LS, Zhang SD, Glazko G,
Yli-Harja O, Dehmer M, Haibe-Kains B and Emmert-Streib F: A review
of connectivity map and computational approaches in
pharmacogenomics. Brief Bioinform. 18:9032017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guedes IA, de Magalhaes CS and Dardenne
LE: Receptor-ligand molecular docking. Biophys Rev. 6:75–87. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rose PW, Prlic A, Bi C, Bluhm WF, Christie
CH, Dutta S, Green RK, Goodsell DS, Westbrook JD, Woo J, et al: The
RCSB protein data bank: Views of structural biology for basic and
applied research and education. Nucleic Acids Res. 43:D345–D356.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim S, Thiessen PA, Bolton EE, Chen J, Fu
G, Gindulyte A, Han L, He J, He S, Shoemaker BA, et al: PubChem
substance and compound databases. Nucleic Acids Res.
44:D1202–D1213. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alexander N, Woetzel N and Meiler J:
bcl::Cluster: A method for clustering biological molecules coupled
with visualization in the Pymol Molecular Graphics System. IEEE Int
Conf Comput Adv Bio Med Sci. 2011:13–18. 2011.PubMed/NCBI
|
|
31
|
Zhang W, Zhang J, Hoadley K, Kushwaha D,
Ramakrishnan V, Li S, Kang C, You Y, Jiang C, Song SW, et al:
miR-181d: A predictive glioblastoma biomarker that downregulates
MGMT expression. Neuro Oncol. 14:712–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jones TA, Jeyapalan JN, Forshew T,
Tatevossian RG, Lawson AR, Patel SN, Doctor GT, Mumin MA, Picker
SR, Phipps KP, et al: Molecular analysis of pediatric brain tumors
identifies microRNAs in pilocytic astrocytomas that target the MAPK
and NF-kB pathways. Acta Neuropathol Commun. 3:862015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Piwecka M, Rolle K, Belter A, Barciszewska
AM, Żywicki M, Michalak M, Nowak S, Naskret-Barciszewska MZ and
Barciszewski J: Comprehensive analysis of microRNA expression
profile in malignant glioma tissues. Mol Oncol. 9:1324–1340. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Onco.
13:e249–e258. 2012. View Article : Google Scholar
|
|
35
|
Ling H, Fabbri M and Calin GA: MicroRNAs
and other non-coding RNAs as targets for anticancer drug
development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dou T, Wu Q, Chen X, Ribas J, Ni X, Tang
C, Huang F, Zhou L and Lu D: A polymorphism of microRNA196a genome
region was associated with decreased risk of glioma in Chinese
population. J Cancer Res Clin Oncol. 136:1853–1859. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang G, Han D, Chen X, Zhang D, Wang L,
Shi C, Zhang W, Li C, Chen X, Liu H, et al: MiR-196a exerts its
oncogenic effect in glioblastoma multiforme by inhibition of IκBα
both in vitro and in vivo. Neuro Oncol. 16:652–661. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Guan Y, Chen L, Bao Y, Qiu B, Pang C, Cui
R and Wang Y: High miR-196a and low miR-367 cooperatively correlate
with unfavorable prognosis of high-grade glioma. Int J Clin Exp
Pathol. 8:6576–6588. 2015.PubMed/NCBI
|
|
40
|
Yang JP, Yang JK, Li C, Cui ZQ, Liu HJ,
Sun XF, Geng SM, Lu SK, Song J, Guo CY and Jiao BH: Downregulation
of ZMYND11 induced by miR-196a-5p promotes the progression and
growth of GBM. Biochem Biophys Res Commun. 494:674–680. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sasayama T, Nishihara M, Kondoh T, Hosoda
K and Kohmura E: MicroRNA-10b is overexpressed in malignant glioma
and associated with tumor invasive factors, uPAR and RhoC. Int J
Cancer. 125:1407–1413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guessous F, Alvarado-Velez M,
Marcinkiewicz L, Zhang Y, Kim J, Heister S, Kefas B, Godlewski J,
Schiff D, Purow B and Abounader R: Oncogenic effects of miR-10b in
glioblastoma stem cells. J Neurooncol. 112:153–163. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gabriely G, Teplyuk NM and Krichevsky AM:
Context effect: microRNA-10b in cancer cell proliferation, spread
and death. Autophagy. 7:1384–1386. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ji Y, Wei Y, Wang J, Gong K, Zhang Y and
Zuo H: Correlation of microRNA-10b upregulation and poor prognosis
in human gliomas. Tumour Biol. 36:6249–6254. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guan Y, Mizoguchi M, Yoshimoto K, Hata N,
Shono T, Suzuki SO, Araki Y, Kuga D, Nakamizo A, Amano T, et al:
MiRNA-196 is upregulated in glioblastoma but not in anaplastic
astrocytoma and has prognostic significance. Clin Cancer Res.
16:4289–4297. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lakomy R, Sana J, Hankeova S, Fadrus P,
Kren L, Lzicarova E, Svoboda M, Dolezelova H, Smrcka M, Vyzula R,
et al: MiR-195, miR-196b, miR-181c, miR-21 expression levels and
O−6-methylguanine-DNA methyltransferase methylation status
are associated with clinical outcome in glioblastoma patients.
Cancer Sci. 102:2186–2190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ma R, Yan W, Zhang G, Lv H, Liu Z, Fang F,
Zhang W, Zhang J, Tao T, You Y, et al: Upregulation of miR-196b
confers a poor prognosis in glioblastoma patients via inducing a
proliferative phenotype. PLoS One. 7:e380962012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
You G, Yan W, Zhang W, Wang Y, Bao Z, Li
S, Li S, Li G, Song Y, Kang C, et al: Significance of miR-196b in
tumor-related epilepsy of patients with gliomas. PLoS One.
7:e462182012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Karsy M, Arslan E and Moy F: Current
progress on understanding MicroRNAs in glioblastoma multiforme.
Genes Cancer. 3:3–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cai J, Zhao J, Zhang N, Xu X, Li R, Yi Y,
Fang L, Zhang L, Li M, Wu J, et al: MicroRNA-542-3p suppresses
tumor cell invasion via targeting AKT pathway in human astrocytoma.
J Biol Chem. 290:24678–24688. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Qian J, Li R, Wang YY, Shi Y, Luan WK, Tao
T, Zhang JX, Xu YC and You YP: MiR-1224-5p acts as a tumor
suppressor by targeting CREB1 in malignant gliomas. Mol Cell
Biochem. 403:33–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ouyang Q, Chen G, Zhou J, Li L, Dong Z,
Yang R, Xu L, Cui H, Xu M and Yi L: Neurotensin signaling
stimulates glioblastoma cell proliferation by upregulating c-Myc
and inhibiting miR-29b-1 and miR-129-3p. Neuro Oncol. 18:216–226.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fang DZ, Wang YP, Liu J, Hui XB, Wang XD,
Chen X and Liu D: MicroRNA-129-3p suppresses tumor growth by
targeting E2F5 in glioblastoma. Eur Rev Med Pharmacol Sci.
22:1044–1050. 2018.PubMed/NCBI
|
|
54
|
Tutar Y: miRNA and cancer; computational
and experimental approaches. Curr Pharm Biotechnol. 15:4292014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Matsui M, Chu Y, Zhang H, Gagnon KT,
Shaikh S, Kuchimanchi S, Manoharan M, Corey DR and Janowski BA:
Promoter RNA links transcriptional regulation of inflammatory
pathway genes. Nucleic Acids Res. 41:10086–10109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Majid S, Dar AA, Saini S, Yamamura S,
Hirata H, Tanaka Y, Deng G and Dahiya R: MicroRNA-205-directed
transcriptional activation of tumor suppressor genes in prostate
cancer. Cancer. 116:5637–5649. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Xiao M, Li J, Li W, Wang Y, Wu F, Xi Y,
Zhang L, Ding C, Luo H, Li Y, et al: miRNA and cancer;
computational and experimental approaches. MicroRNAs activate gene
transcription epigenetically as an enhancer trigger. RNA Biol.
14:1326–1334. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Aramadhaka LR, Prorock A, Dragulev B, Bao
Y and Fox JW: Connectivity maps for biosimilar drug discovery in
venoms: The case of Gila monster venom and the anti-diabetes drug
Byetta®. Toxicon. 69:160–167. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang J, Li M, Wang Y and Liu X:
Integrating subpathway analysis to identify candidate agents for
hepatocellular carcinoma. Onco Targets Ther. 9:1221–1230. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Strobl JS and Peterson VA:
Tamoxifen-resistant human breast cancer cell growth: Inhibition by
thioridazine, pimozide and the calmodulin antagonist, W-13. J
Pharmacol Exp Ther. 263:186–193. 1992.PubMed/NCBI
|
|
61
|
Takadera T and Ohyashiki T: Calmodulin
inhibitor-induced apoptosis was prevented by glycogen synthase
kinase-3 inhibitors in PC12 cells. Cell Mol Neurobiol. 27:783–790.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mu L, Wang T, Chen Y, Tang X, Yuan Y and
Zhao Y: β-Elemene enhances the efficacy of gefitinib on
glioblastoma multiforme cells through the inhibition of the EGFR
signaling pathway. Int J Oncol. 49:1427–1436. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Parker JJ, Dionne KR, Massarwa R, Klaassen
M, Foreman NK, Niswander L, Canoll P, Kleinschmidt-Demasters BK and
Waziri A: Gefitinib selectively inhibits tumor cell migration in
EGFR-amplified human glioblastoma. Neuro Oncol.
15:1048–1057. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Aljohani H, Koncar RF, Zarzour A, Park BS,
Lee SH and Bahassi el M: ROS1 amplification mediates resistance to
gefitinib in glioblastoma cells. Oncotarget. 6:20388–20395. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Barton MK: Exemestane is effective for the
chemoprevention of breast cancer. CA Cancer J Clin. 61:363–364.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Pagani O, Regan MM and Francis PA:
Exemestane with ovarian suppression in premenopausal breast cancer.
N Engl J Med. 371:1358–1359. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Van Asten K, Neven P, Lintermans A,
Wildiers H and Paridaens R: Aromatase inhibitors in the breast
cancer clinic: Focus on exemestane. Endocr Relat Cancer.
21:R31–R49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kritikou I, Giannopoulou E, Koutras AK,
Labropoulou VT and Kalofonos HP: The combination of antitumor
drugs, exemestane and erlotinib, induced resistance mechanism in
H358 and A549 non-small cell lung cancer (NSCLC) cell lines. Pharm
Biol. Nov 5–2013.(Epub ahead of print). PubMed/NCBI
|
|
69
|
Che TF, Lin CW, Wu YY, Chen YJ, Han CL,
Chang YL, Wu CT, Hsiao TH, Hong TM and Yang PC: Mitochondrial
translocation of EGFR regulates mitochondria dynamics and promotes
metastasis in NSCLC. Oncotarget. 6:37349–37366. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Cao X, Zhu H, Ali-Osman F and Lo HW: EGFR
and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced
mitochondrial translocalization: A potential mechanism of
EGFR-driven antagonism of apoptosis. Mol Cancer. 10:262011.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Dasari VR, Velpula KK, Alapati K, Gujrati
M and Tsung AJ: Cord blood stem cells inhibit epidermal growth
factor receptor translocation to mitochondria in glioblastoma. PLoS
One. 7:e318842012. View Article : Google Scholar : PubMed/NCBI
|
